Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The monoclonal antibody combo is used as pre-exposure prophylaxis for immunocompromised people who may not respond to COVID-19 vaccines.
EBV is associated with certain cancers, including Hodgkin lymphoma, and autoimmune diseases, such as multiple sclerosis.
Get a COVID booster, especially if you’re older or your immune system is compromised, and don’t forget the flu shot.
People diagnosed with cancer over a year ago and those who were not on treatment did not have a higher risk of hospitalization or death.
Cancer patients undergoing treatment and those with suppressed immune systems eye the future—and the COVID pandemic’s wane—warily.
Molnupiravir, the first oral antiviral for COVID-19, reduces the risk of hospitalization or death if started within five days.
Post-exposure and pre-exposure prophylaxis could be a game-changer for immunocompromised people.
NIAID director Anthony Fauci, MD, and coauthors emphasize the need for a global response to COVID-19.
Certain racial/ethnic groups and older people aren’t being adequately represented and trial reporting guidelines aren’t being followed.
Bamlanivimab and etesevimab may be given to people with mild to moderate COVID-19 who are at high risk for progression to severe disease.
Even as drugmakers ramp up supplies, only a trickle of the product has found its way into regular people.
The ACTIV-2 study aims to determine whether neutralizing antibodies reduce the duration of COVID-19 symptoms.
Bamlanivimab did not speed clinical improvement or reduce the time to hospital discharge or sustained recovery.
Two Phase III clinical trials are evaluating monoclonal antibodies for people hospitalized with moderate COVID-19.
Immune cells called T cells helped prevent reinfection and may be especially important if antibody levels are low or decline over time.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.